Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock Position Boosted by BNP Paribas Financial Markets

BNP Paribas Financial Markets lifted its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 172.9% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 32,078 shares of the biotechnology company’s stock after acquiring an additional 20,324 shares during the quarter. BNP Paribas Financial Markets’ holdings in Aurinia Pharmaceuticals were worth $235,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. FMR LLC grew its stake in shares of Aurinia Pharmaceuticals by 44.8% in the 3rd quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock worth $93,000 after purchasing an additional 3,919 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Aurinia Pharmaceuticals by 10.0% in the second quarter. The Manufacturers Life Insurance Company now owns 52,747 shares of the biotechnology company’s stock worth $301,000 after acquiring an additional 4,808 shares in the last quarter. Banque Cantonale Vaudoise increased its position in shares of Aurinia Pharmaceuticals by 126.6% in the second quarter. Banque Cantonale Vaudoise now owns 9,684 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 5,410 shares in the last quarter. Handelsbanken Fonder AB increased its position in shares of Aurinia Pharmaceuticals by 13.2% in the third quarter. Handelsbanken Fonder AB now owns 60,700 shares of the biotechnology company’s stock worth $445,000 after acquiring an additional 7,100 shares in the last quarter. Finally, PFG Investments LLC increased its position in shares of Aurinia Pharmaceuticals by 37.9% in the second quarter. PFG Investments LLC now owns 28,750 shares of the biotechnology company’s stock worth $164,000 after acquiring an additional 7,900 shares in the last quarter. Institutional investors and hedge funds own 36.83% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on AUPH shares. StockNews.com downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday. Cantor Fitzgerald restated an “overweight” rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a report on Monday, September 16th. Finally, HC Wainwright restated a “buy” rating and set a $13.00 price target on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Aurinia Pharmaceuticals Stock Performance

AUPH stock opened at $9.63 on Tuesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The stock has a market cap of $1.38 billion, a P/E ratio of -63.33 and a beta of 1.41. The firm has a 50 day simple moving average of $8.03 and a 200 day simple moving average of $6.76. Aurinia Pharmaceuticals Inc. has a 52 week low of $4.71 and a 52 week high of $10.67.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other news, Director Jeffrey Allen Bailey sold 4,557 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $8.43, for a total value of $38,415.51. Following the transaction, the director now owns 13,356 shares of the company’s stock, valued at $112,591.08. This trade represents a 25.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.30% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.